Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Identifying and addressing ethical issues are key to the success of any clinical trials, particularly when working with vulnerable populations. Tackling these issues helps improve the quality of research and translate the evidence of clinical trials into improvement of management of patients.

Q: Why is it important that we pay attention to the ethics of research?

Phaik Yeong Cheah: In my opinion, ethical issues are inherent in clinical research.

They are very important in all aspects of clinical research: through experience of working in this area for a long time, I have found that identifying and addressing ethical issues is key to the success of any clinical trial. This helps improve the quality of trials, and in translating the evidence from clinical trials towards improving patient managment.

Q: What particularly interests you about research ethics?

PYC: Ethical principles are in my opinion universal. I work in the Thailand major overseas programme which operates in low income settings and works with vulnerable populations and neglected diseases.

Translating these supposedly universal ethical issues is an exciting challenge and I am very passionate about it. Operationalising ethical guidelines in these low income settings and vulnerable populations is very interesting and it enables good research to be done in these settings. But we have to contextualise these principles to make them practical day-to-day: when we recruit patients and we gain consent, when we talk about ancillary care etc.

Q: How has your work changed the way scientists actually do their research?

PYC: First of all, I would hope my work does change the way scientists do their work! I see work on ethics as something that is more enabling than disabling.Scientists who might have seen ethics as a hurdle now see ethics are enabling: it helps scientists who conduct research in ethically charged situations to look at their research studies in a different light, and dissect the ethical issues better.

For example, when conducting work in vulnerable populations like pregnant women, children or migrant workers, recruiting these subjects into clinical trials is challenging.

Q: What are the most important lines of research that you think have emerged in this area of the last 5-10 years?

PYC: I think the area of empirical ethics and research about community engagement in clinical trials is an important one, although there are many others. Gathering data to inform what one should do in an ethical dilemma is an interesting development in the research world. Community engagement is a new thing, as well as research into elements surrounding evaluation. And when we talk about the community: who are they? Who is the community? How do we define representatives of the community?

I have been personally involved in facilitating a community advisory board and it has been really interesting running that board. The community is on the Thai/Burmese border, which is an area where the population is mobile and moves between Thailand and Burma. Trying to understand the notion of community is an interesting concept.

Q: Why is your research important and why should we fund it?

PYC: In essence, I believe that there is not enough research in this area. In particular, research into vulnerable populations (I am talking about children, pregnant woman and other vulnerable groups) is lacking. I think that's because people are afraid of these populations and traditionally the scientific community has tended towards the view of protecting these populations from research. The view has moved from protecting them from research to protecting them through research. With that comes a lot of ethical issues that have to be sorted out, considered, worked through and operationalised in day-to-day practice.

Q: How does your work fit in with translational medicine within the department?

PYC: I would think that it is through policies and guidelines. My work in South East Asia and more widely in low income settings has influenced policies either directly or indirectly through recommendations. This I see as very important because the international guidelines are developed in the West and to translate that to low income settings is quite a challenge. Having worked in low income settings, the data we produce on the ground feeds into these guidelines and helps researchers translate them into every day practice.

Phaik Yeong Cheah

Professor Phaik Yeong Cheah leads the Department of Bioethics & Engagement at the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Thailand. She is particularly interested in ethical issues in community engagement, data sharing, consent and assent in paediatric research.

More podcasts related to Global Health

Mike English: Health services that deliver for newborns

Basic hospital care may be key to saving newborn lives. Professor Mike English outlines a multidisciplinary project engaging policy-makers and practitioners in Kenya. This project demonstrated poor coverage of Nairobi’s 4.25 million population if a sick newborn baby needs quality hospital care. Using novel research approaches the team also identified how severe shortages of nurses contribute to poor quality of care for patients and negatively affect nurses themselves.

Tran Hien: Infectious diseases in the tropics

Although incidence of malaria has decreased in Vietnam, the burden of infectious diseases remains high and weighs heavily on the health care system. Clinical research aims to allow investments to go further: findings in the laboratory, tested in clinical trials and then applied to the community, help improve diagnosis and management.

Ronald Geskus: Sophisticated biostatistics for complex clinical research

The role of biostatisticians in clinical research is to contribute to trial design, by calculating sample size for example, and to help draw correct conclusions from the data, discriminating important information from noise. They are instrumental in the translation of a practical problem into a statistical model, and the translation of the result into practice.

Rogier Van Doorn: Research at OUCRU Hanoi

Antibiotics are widely used in Vietnam, leading to widespread antimicrobial resistance. Monitoring antibiotic use helps inform the government to change treatment guidelines and implement antibiotic stewardship programmes. This may also prevent the transmission of resistant bacteria outside the country.

Heiman Wertheim: Clinical research in low and middle-income countries

Drug resistant infections are a global crisis and we cannot focus on our own country only. Clinical trials in low and middle income countries where the burden is highest, as well as work with local communities and engagement with policy makers help influence public health policies.

Guy Thwaites: Tuberculosis meningitis

Tuberculosis meningitis affects a fractions of TB patients but causes high levels of mortality and morbidity. A recent trial at OUCRU showed that aspirin can greatly improve outcomes. Such trial is typical of the work done in our Vietnam units, where all the research is focussed on improving the outcome for patients directly.

Motiur Rahman: OUCRU laboratory management

OUCRU laboratories provide support to the unit’s extensive clinical research programme, from level 2 laboratory to SAPO 4 laboratory for high-risk pathogens responsible for zoonotic infections. Early diagnosis and detection of antimicrobial resistance helps prescribe the right medicine in time, contributing to better patient management.

Raph Hamers: Developing collaborative clinical trials in Indonesia

Indonesia is a very populous country with a huge burden of infectious diseases such as TB, malaria, HIV and CNS infections. Running clinical trials requires high levels of expertise, currently developed and strengthened by institutions such as IOCRL (Universities of Indonesia and Oxford Clinical Research laboratory). Better collaborations will also help great ideas make a bigger impact.

Jeremy Day: Central nervous system and HIV infections in Vietnam

Brain infections such as meningitis and encephalitis are highly debilitating diseases, and an accurate diagnostic is essential to give patients the best treatment available. For cryptococcal meningitis, clinical trials focus on prevention, for an early diagnosis, and novel ways to use existing treatments or repurpose old drugs.

Abhilasha Karkey: Connecting research with communities in Nepal

Antimicrobial resistance is a huge burden in Nepal, particularly in hospitals where many nosocomial infections are caused by resistant pathogens. With limited resources, little infection controls and proper guidelines in place, finding out the main risk factors helps reduce infection rates within a hospital and better target vaccination campaigns.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.